

Julie Earl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2088710/publications.pdf>

Version: 2024-02-01

48
papers

1,757
citations

471371

17
h-index

315616

38
g-index

51
all docs

51
docs citations

51
times ranked

4034
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. <i>Gut</i> , 2023, 72, 345-359.	6.1	15
2	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. <i>Gastroenterology</i> , 2022, 162, 772-785.e4.	0.6	60
3	Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. <i>EBioMedicine</i> , 2022, 75, 103797.	2.7	20
4	Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00468.	1.3	17
5	DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2117.	1.8	8
6	Ultrasounds in cancer therapy: A summary of their use and unexplored potential. <i>Oncology Reviews</i> , 2022, 16, 531.	0.8	5
7	Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study. <i>Future Science OA</i> , 2022, 8, .	0.9	2
8	The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16239-e16239.	0.8	0
9	Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. <i>Cancers</i> , 2021, 13, 1612.	1.7	3
10	Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. <i>Cancers</i> , 2021, 13, 1710.	1.7	7
11	Giant Macrophages: Characteristics and Clinical Relevance. , 2021, , 169-184.		0
12	ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. <i>Nature Communications</i> , 2020, 11, 2682.	5.8	63
13	Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4091.	1.8	17
14	A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. <i>EBioMedicine</i> , 2020, 53, 102675.	2.7	29
15	Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers. <i>United European Gastroenterology Journal</i> , 2019, 7, 682-688.	1.6	3
16	Towards a more sensitive detection of somatic mutations in cell-free DNA. <i>EBioMedicine</i> , 2019, 41, 23.	2.7	1
17	Tumor-associated macrophage-secreted 14-3-3 \uparrow signals via AXL to promote pancreatic cancer chemoresistance. <i>Oncogene</i> , 2019, 38, 5469-5485.	2.6	57
18	Reply to "Mosaic loss of chromosome Y in leukocytes matters". <i>Nature Genetics</i> , 2019, 51, 7-9.	9.4	7

#	ARTICLE	IF	CITATIONS
19	Circulating endothelial cells: Prognostic value in patients with glioblastoma.. Journal of Clinical Oncology, 2019, 37, e13517-e13517.	0.8	1
20	Ultrasound Technology as a Novel Treatment Strategy in Pancreatic Cancer. Novel Approaches in Cancer Study, 2019, 2, .	0.2	1
21	Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Oncotarget, 2018, 9, 32984-32996.	0.8	27
22	A Label Free Disposable Device for Rapid Isolation of Rare Tumor Cells from Blood by Ultrasounds. Micromachines, 2018, 9, 129.	1.4	16
23	Differential distribution and enrichment of non-coding RNAs in exosomes from normal and Cancer-associated fibroblasts in colorectal cancer. Molecular Cancer, 2018, 17, 114.	7.9	61
24	Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nature Genetics, 2016, 48, 563-568.	9.4	134
25	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Journal of Clinical Oncology, 2016, 34, 2010-2019.	0.8	280
26	Circulating biomarkers exploratory study in loco-regional gastroesophageal adenocarcinoma patients.. Journal of Clinical Oncology, 2016, 34, 17-17.	0.8	0
27	Compliance and impact of screening on individuals at high risk of breast and ovarian cancer syndrome (BOCS).. Journal of Clinical Oncology, 2016, 34, e13054-e13054.	0.8	0
28	Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer, 2015, 15, 797.	1.1	147
29	Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?. Clinical Genitourinary Cancer, 2015, 13, 493-498.	0.9	7
30	Biomarkers for early diagnosis of pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 305-315.	1.4	36
31	The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics, 2015, 16, 403.	1.2	86
32	Prognostic factors in advanced gastric cancer after second-line treatment.. Journal of Clinical Oncology, 2015, 33, 201-201.	0.8	0
33	Genetic and phenotypic characterization of families with familial pancreatic cancer and screening of high-risk individuals.. Journal of Clinical Oncology, 2015, 33, 242-242.	0.8	0
34	KRAS mutant circulating free DNA (cfDNA) and circulating tumor cell (CTC) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, e15252-e15252.	0.8	0
35	Rectal adenocarcinoma: Results of adjuvant chemotherapy in a retrospective cohort.. Journal of Clinical Oncology, 2015, 33, e14539-e14539.	0.8	0
36	Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution.. Journal of Clinical Oncology, 2014, 32, e15019-e15019.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. <i>Nature Genetics</i> , 2013, 45, 1464-1469.	9.4	224
38	sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4140-4140.	0.8	17
39	Imaging techniques in pancreatic cancer screening: Preliminary results from the PanGen-FAM registry.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1529-1529.	0.8	0
40	Common genetic variants in the <i>PSCA</i> gene influence gene expression and bladder cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 4974-4979.	3.3	79
41	New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 457-467.	1.1	7
42	Spanish national hereditary pancreatic cancer registry (PanFAM).. <i>Journal of Clinical Oncology</i> , 2012, 30, e12033-e12033.	0.8	0
43	Mosaic Uniparental Disomies and Aneuploidies as Large Structural Variants of the Human Genome. <i>American Journal of Human Genetics</i> , 2010, 87, 129-138.	2.6	111
44	Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20780-20785.	3.3	84
45	Single-Nucleotide Polymorphism (SNP) Analysis to Associate Cancer Risk. <i>Methods in Molecular Biology</i> , 2009, 576, 171-196.	0.4	7
46	Palladin Mutation Causes Familial Pancreatic Cancer: Absence in European Families. <i>PLoS Medicine</i> , 2007, 4, e164.	3.9	54
47	Evaluation of the 4q32-34 Locus in European Familial Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1948-1955.	1.1	50
48	Development of Temporal Temperature Gradient Electrophoresis for Characterising Methanogen Diversity. <i>Microbial Ecology</i> , 2005, 50, 327-336.	1.4	10